Oligonucleotide decoys for the treatment of pain
AssigneeAdynxx, Inc.
InventorsJulien Mamet, Rick Orr, Don Manning, Scott Harris, William Martin
Life of this patent
Estimating the term…
Abstract
Provided are therapeutic agents such as double-stranded nucleic acids, termed oligonucleotide decoys, pharmaceutical compositions comprising the same, and related methods of modulating nociceptive signaling, for instance, to prevent and/or treat pain.
Claims31
An oligonucleotide decoy comprising a combination of at least two transcription factor binding sites, wherein each transcription factor binding site binds to a transcription factor selected from the group consisting of KLF1, KLF2, KLF3, KLF4, KLF5, KLF6, KLF7, KLF8, KLF9, KLF10, KLF11, KLF12, KLF13, KLF14, KLF15, KLF16 and KLF17.
An oligonucleotide decoy comprising a sequence represented by Formula 1 or Formula 2:
- a1t2c3c4T5T6Y7G8M9M10T11YnYnK14Y15C16N17H18h19n20n21v22n23n24h25m26h27w28b29v30a31w32 (Formula 1;
- SEQ ID NO:1)
- t1g2t3k4b5K6K7D8D9V10D11N12S13D14N15B16N17N18d19v20m21b22v23m24h25r26m27a28 (Formula 2;
- SEQ ID NO:2)
- wherein S is G or C;
- W is A or T;
- Y is T or C;
- D is A, G, or T;
- B is C, G, or T;
- K is T or G;
- M is C or A;
- H is C, T, or A;
- V is C, G, or A;
- R is A or G;
- and N is any nucleotide, wherein lower case letters can be either present or absent, and wherein the numbers in subscript represent the position of a nucleotide in the sequence.
A method for modulating nociceptive signaling in a cell comprising administering to the cell a therapeutically effective amount of a therapeutic agent, wherein the therapeutic agent inhibits binding of a transcription factor to its transcription factor binding site, wherein the transcription factor is selected from the group consisting of KLF1, KLF2, KLF3, KLF4, KLF5, KLF6, KLF8, KLF9, KLF10, KLF11, KLF12, KLF13, KLF14, KLF15, KLF16 and KLF17.
A method for treating pain in a subject comprising administering to the subject a therapeutically effective amount of a therapeutic agent, wherein the therapeutic agent inhibits binding of a transcription factor to its transcription binding site, wherein the transcription factor is selected from the group consisting of KLF1, KLF2, KLF3, KLF4, KLF5, KLF6, KLF8, KLF9, KLF10, KLF11, KLF12, KLF13, KLF14, KLF15, KLF16 and KLF17.
Dependencies are inferred from the claim text.